Molecular subtype assay to reveal anti-EGFR response sub-clones in colorectal cancer (CRC).
Elisa Fontana(Sarah Cannon Research Institute), Anguraj Sadanandam(Institute of Cancer Research), Ian Chau(Royal Marsden NHS Foundation Trust), Chanthirika Ragulan(Royal Marsden NHS Foundation Trust), Katherine Eason(University of Cambridge), I. Vendrell(Centro Hospitalar Lisboa Norte), Jenkev Samantha Sing Yu Moorcraft(Royal Marsden NHS Foundation Trust), David Cunningham(Royal Marsden NHS Foundation Trust), Gift Nyamundanda(Institute of Cancer Research), Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), Francesco Sclafani(Royal Marsden NHS Foundation Trust), Ruwaida Begum, Sanna Hulkki Wilson(Royal Marsden NHS Foundation Trust), Yatish Patil(Royal Marsden NHS Foundation Trust), Naureen Starling(Royal Marsden NHS Foundation Trust)
Cited by 9
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k